Literature DB >> 24630396

Altered expression and localization of desmoglein 3 in esophageal squamous cell carcinoma.

Wang-Kai Fang1, Bo Chen2, Xiu-E Xu2, Lian-Di Liao2, Zhi-Yong Wu3, Jian-Yi Wu4, Jian Shen2, Li-Yan Xu5, En-Min Li6.   

Abstract

Desmoglein 3 (DSG3), a transmembrane cadherin of the desmosomal cell-cell adhesion structure, plays vital roles in the maintenance of normal epithelial tissue architecture. Reports implicating a role for DSG3 expression in cancer are few and contradictory. In this study, immunohistochemical staining was employed to investigate DSG3 expression and subcellular localization in esophageal squamous cell carcinoma (ESCC), and to correlate changes with clinical characteristics. Results indicate that in normal squamous cell epithelia, strong DSG3 immunoreactivity was observed in the Stratum spinosum, and localization occurred only at the cell membrane. In ESCC, DSG3 immunoreactivity displayed an abnormal cytoplasmic localization that was correlated with cell differentiation (P=0.018). Most strikingly, in 74.1% of the tumors, DSG3 expression was up-regulated and correlated with regional lymph node metastasis (P=0.036). Moreover, in patients without lymph node metastasis, cytoplasmic localization of DSG3 correlated with poor prognosis (P=0.044). These results suggest that DSG3 is involved in the development of ESCC and imply that DSG3 overexpression is likely to be an essential contributor to the aggressive features of esophageal cancer.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Desmoglein 3; Esophageal squamous cell carcinoma; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 24630396     DOI: 10.1016/j.acthis.2014.01.010

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  5 in total

1.  Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.

Authors:  Daniel T Merrick; Michael G Edwards; Wilbur A Franklin; Michio Sugita; Robert L Keith; York E Miller; Micah B Friedman; Lori D Dwyer-Nield; Meredith A Tennis; Mary C O'Keefe; Elizabeth J Donald; Jessica M Malloy; Adrie van Bokhoven; Storey Wilson; Peter J Koch; Charlene O'Shea; Christopher Coldren; David J Orlicky; Xian Lu; Anna E Baron; Greg Hickey; Timothy C Kennedy; Roger Powell; Lynn Heasley; Paul A Bunn; Mark Geraci; Raphael A Nemenoff
Journal:  Cancer Res       Date:  2018-07-11       Impact factor: 12.701

Review 2.  Desmoglein 3: a help or a hindrance in cancer progression?

Authors:  Louise Brown; Hong Wan
Journal:  Cancers (Basel)       Date:  2015-01-26       Impact factor: 6.639

3.  Nephroprotective effects of diacylglycerol on diabetic nephropathy in type 2 diabetic rats.

Authors:  Jianpeng Li; Yongheng Yan; Duo Li; Xia Li; Xinying Lin; Zhenhua Liu; Tongcheng Xu; Fangling Du
Journal:  Exp Ther Med       Date:  2017-12-18       Impact factor: 2.447

4.  Tissue-specific effects of an anti-desmoglein-3 ADCC antibody due to expression of the target antigen and physiological characteristics of the mouse vagina.

Authors:  Etsuko Fujii; Shinichi Funahashi; Kenji Taniguchi; Shigeto Kawai; Kiyotaka Nakano; Atsuhiko Kato; Masami Suzuki
Journal:  J Toxicol Pathol       Date:  2019-12-19       Impact factor: 1.628

5.  Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.

Authors:  Shin-Ichi Funahashi; Shigeto Kawai; Etsuko Fujii; Kenji Taniguchi; Kiyotaka Nakano; Shumpei Ishikawa; Hiroyuki Aburatani; Masami Suzuki
Journal:  J Biochem       Date:  2018-12-01       Impact factor: 3.387

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.